Data Insights

IBI-343 by Innovent Biologics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - IBI-343 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

IBI-343 by Innovent Biologics for Gastric Cancer: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IBI-343 in Gastric Cancer

Data Insights

IBI-343 by Innovent Biologics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Data Insights

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Data Insights

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Data Insights

IBI-343 by Innovent Biologics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...